TRACKING THE CELLULAR ORIGINS AND PREDICTIVITY OF CIRCULATING EXTRACELLULAR VESICLES IN CAR-T THERAPY (SIE 2026) - Oct 6, 2026 - Abstract #DP033; Pres time: Sep 21, 2026; 07:00 PM - 08:00 PM; Location: AREA POSTER; "Approved products include axicabta- gene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and brex- ucabtagene autoleucel (brexu-cel). Additionally, dynamic increases in CD146+ EC EVs may signal endothelial roles in NT. Larg- er prospective trials are required to better characterize EV immunophenotypes and their connection to inflammatory and endothelial processes."
CAR T-Cell Therapy • IO biomarker • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD31 • MCAM • PECAM1 • PTPRC
|
|
A. Melis1,2; G. Lia1,2; M. Dicataldo1,2; F. Ferrando1,2; I. Dogliotti2; A. Busca2; S. Ragaini1; V. Granero3; B. Botto4; M. Clerico5; M. Novo4; F. Cavallo6; L. Giaccone6; B. Bruno6
|